| 000 | 01535 a2200385 4500 | ||
|---|---|---|---|
| 005 | 20250517201600.0 | ||
| 264 | 0 | _c20190124 | |
| 008 | 201901s 0 0 eng d | ||
| 022 | _a1756-8927 | ||
| 024 | 7 |
_a10.4155/fmc-2017-0298 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aDayal, Neetu | |
| 245 | 0 | 0 |
_aDual FLT3/TOPK inhibitor with activity against FLT3-ITD secondary mutations potently inhibits acute myeloid leukemia cell lines. _h[electronic resource] |
| 260 |
_bFuture medicinal chemistry _c04 2018 |
||
| 300 |
_a823-835 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't | ||
| 650 | 0 | 4 |
_aAntineoplastic Agents _xpharmacology |
| 650 | 0 | 4 | _aCell Line, Tumor |
| 650 | 0 | 4 | _aDrug Resistance, Neoplasm |
| 650 | 0 | 4 |
_aG1 Phase _xdrug effects |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aLeukemia, Myeloid, Acute _xdrug therapy |
| 650 | 0 | 4 |
_aMitogen-Activated Protein Kinase Kinases _xantagonists & inhibitors |
| 650 | 0 | 4 | _aMutation |
| 650 | 0 | 4 |
_aProtein Kinase Inhibitors _xpharmacology |
| 650 | 0 | 4 |
_afms-Like Tyrosine Kinase 3 _xantagonists & inhibitors |
| 700 | 1 | _aOpoku-Temeng, Clement | |
| 700 | 1 | _aHernandez, Delmis E | |
| 700 | 1 | _aSooreshjani, Moloud Aflaki | |
| 700 | 1 | _aCarter-Cooper, Brandon A | |
| 700 | 1 | _aLapidus, Rena G | |
| 700 | 1 | _aSintim, Herman O | |
| 773 | 0 |
_tFuture medicinal chemistry _gvol. 10 _gno. 7 _gp. 823-835 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.4155/fmc-2017-0298 _zAvailable from publisher's website |
| 999 |
_c28080013 _d28080013 |
||